| Tasimelteon | Vanda pharma | ||
| 20 mg; Capsule, Oral |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
|
Less Than 5
|
Less Than 5
|
||
| Indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). | |||
|
Yes
| |||
| Hetlioz | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 | Patent 23 | Patent 24 | Patent 25 | Patent 26 | Patent 27 | Patent 28 | Patent 29 | Patent 30 | Patent 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **** | ********* | *** ** ** *** ** | **** *** | ********* ** ****** ** **** | ********* ** ****** ** **** | ********* ** ****** ** **** | *** ** ** *** ** | ********* ** ****** ** **** | *** ** ** *** ** | *** ** ** *** ** | ********* ** ****** ** **** | **** ** *** **, **** | ********* ** ****** ** **** | *** ********* | **** ** *** **, **** | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | **** ** *** **, **** (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | **** ** *** **, **** (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) |
| ****** | ********* | *** ** ** *** ** | **** *** | ********* ** ***** ** ****** | ********* ** ***** ** ****** | ********* ** ***** ** ****** | *** ** ** *** ** | ********* ** ***** ** ****** | *** ** ** *** ** | *** ** ** *** ** | ********* ** ***** ** ****** | *** ********* | ********* ** ***** ** ****** | *** ********* | *** ********* | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | **** ** *** **, **** (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | **** ** *** **, **** (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) |
| *** **** | ******* | ******* | **** *** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | *** ********* | *** ********* | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| **** | *** \** | *** **, **** | ******* / *** ** ** *** ** | ******** | ******** '**-****' ** *** **, **** |
| ****** | *** \ *** | *** *, **** | ******* / *** ** ** *** ** | ******** | ******** '**-****' ** *** **, **** |
| *** **** | *** \ *** | *** *, **** | ******* | ******** | ******** ** *** **, **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|